Health Care Delivery

Patients with pulmonary arterial hypertension (PAH) related to connective tissue disorders (CTDs) and patients with PAH related to another condition accrued higher costs and higher health care resource use (HRU) vs patients who had CTD without PH.

A federal ruling could undermine the framework of FDA drug approvals; Florida’s warning on COVID-19 vaccines omits key data; uninsured patients with cancer struggle to find care.

This 4-day event drew thousands of health care leaders to Nashville, Tennessee; in this column, Ron Southwick, editor of Chief Healthcare Executive, shares his thoughts from conversations and panels in Music City.

This retrospective study examined food insecurity and neighborhood disadvantage in health system patients as predictors of acute health care utilization.

Health systems may be better able to support adoption of chronic care management processes, which have a strong evidence base for practice implementation, compared with patient engagement strategies, which have less evidence to guide effective implementation.

Banner|Aetna has partnered with Virta and their diabetes reversal program, which now has data on outcomes and patient populations served so far.

A ruling by District Judge Reed O’Connor on March 30 called the future of preventive care access into question.

Data from the PANORAMA-HF and PARADIGM-HF trials support the recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

The new research could help identify ways to preserve neuromuscular junctions.

Pollen may contribute to an increased risk of asthma attacks and asthma-related emergency visits, according to one study.

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, speaks on current indications for Rebyota (fecal microbiota, live-jslm) in the treatment of recurrent Clostridioides difficile infection (CDI), as well as coverage and access-related implications for the drug.

Close to 80% of what influences how long someone is going to live is where and how they live, and we need to pay more attention to that or we’re not paying attention to everything that affects their lives, explained David A. Eagle, MD, of New York Cancer & Blood Specialists.

Although they note that their risk combination model needs validation, investigators argue that their insights should guide recommendations for risk stratification and management of these patients.

Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, spoke on how her organization’s tech platform incorporates social determinants of health (SDOH) in care navigation to ensure high quality care and treatment.

The ruling of Braidwood Management v Becerra puts HIV pre-exposure prophylaxis (PrEP) coverage at risk, potentially leading to more than 2000 preventable HIV infections in the coming year.

Racial and ethnic disparities are apparent among Black patients with pulmonary fibrosis (PF), including earlier onset of death, according to a recent study.

Investigators found that surgical intervention for epilepsy improves social functioning and increases the likelihood a patient will be free of seizures.

A 6-item teamwork measure with good construct validity correlated with favorable provider outcomes including work experience, burnout, and intent to stay with the organization.

Between 2019 and 2020, there were 97 reported shortages among sponsor-reported antiseizure medications in Australia, 93% of which were generic brands.

The keynote session highlighted trends in COVID-19 and other respiratory illness rates, a bounce back in health care utilization, biosimilar market trends, new product launches, and more.

Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023.

Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, discussed how the transition to value-based care can contribute to operational and financial risks among oncology practices, and the effectiveness of care navigation platforms in addressing these concerns.

In this AMCP Market Insights session, panelists discussed best practices and challenges when it comes to prescribing antibody drug conjugates, from the payer, provider, and patient perspectives, based on survey findings.

Although adults hospitalized with COVID-19, the flu, or respiratory syncytial virus are often administered antibiotics, the drugs have no effect on reducing the risk of death, according to a new study.

Digital health data can facilitate the participation of underrepresented and diverse patient populations in clinical trials, but first the FDA must build its capability to evaluate such information in its regulatory processes for new drug development.

The Community Oncology Alliance (COA) retains the spirit of an upstart advocacy group, while working to look ahead at innovative technologies, care delivery trends, and other events that threaten independent practices, said oncology leaders while attending their annual meeting this week.

Dupilumab is the first biologic to significantly improve lung function in chronic obstructive pulmonary disease (COPD), according to topline results released Thursday.

Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology; deputy director; and chief scientific officer at Miami Cancer Institute, spoke on the short- and long-term goals for Miami Cancer Institute’s Center for Equity in Cancer Care & Research in improving minority patient enrollment in clinical trials.

On the first full day of conference activity at AMCP 2023, a morning session examined prior authorization (PA) through a lens of refining the current process and the potential role of clinical trial data in PA criteria.

Minnesota looks to create abortion refuge for patients and providers; Moderna’s expected price single dose of COVID-19 sits at $130; FDA staff sees a "clinical benefit" in Biogen’s ALS drug.